Oncology
From the Journals
ORATOR2 mute on best de-escalation therapy for low-risk HPV+ oropharynx cancers
The trial was halted early due to excess deaths in the surgery arm before type of optimal deescalation therapy could be answered.
From the Journals
Genetic counseling for cancer often costs patients nothing
Genetic counseling is an important feature of cancer care that can affect treatment decisions and surveillance. But coverage of genetic counseling...
From the Journals
Updates on treatment/prevention of VTE in cancer patients
“Because patients with cancer have a baseline increased risk of VTE, compared with patients without cancer, the combination of both COVID-19 and...
Latest News
Blood test for cancer available, but is it ready for prime time?
“The devil is in the details to ensure the test can accurately detect very early cancers and there is a pathway for subsequent workup.”
Latest News
Power-morcellation hysterectomies declined and most performed with no containment bag
Despite a possible overestimation of risk by the 2014 FDA safety warning about power morcellators, there has been an almost total nationwide...
From the Journals
Is prostasin a clue to diabetes/cancer link?
Elevated plasma prostasin levels may be a potential biomarker of diabetes and cancer mortality, according to a Swedish prospective, population-...
From the Journals
New blood test could reshape early CRC screening
A new assay that identifies a specific combination of microRNA strands may expand colorectal cancer screening to younger ages in the face of...
From the Journals
‘Misleading’ focus on urinary symptoms preventing early prostate cancer diagnoses
There was “no evidence of a causal link between prostate cancer and either prostate size or troublesome male urinary symptoms,” the authors of a...
From the Journals
Patient CRC screening preferences don’t match what they’re being offered
The greater preference for noninvasive screening tests over a colonoscopy may partly explain stagnant screening rates, experts suggest.
From the Journals
One in four NSCLC patients respond poorly to COVID-19 vaccine
The reasons are unclear, but point to the need for NSCLC patients to have titers checked.
From the Journals
Treatment combo shows ‘clinical benefit’ in liver cancer trial
Combined TKI and ICI inhibitor shows clinical benefit, but it isn’t yet a candidate for first-line therapy.